How Access Challenges Impact the Drug Development Pipeline

In this episode, we dive into the pharmaceutical industry's research and drug development side and the real threat that today’s access and affordability challenges and policies pose to innovation. While innovation often starts in universities with government support, biotech, and pharma companies take on the tough, costly job of clinical trials, development, and approval of new drugs. Investment dollars are limited, only the most promising projects get funded, with an expectation there will be a return. However, our current drug payment process and policies like the IRA have added new considerations for investors, risking fewer new drugs being developed. Without changes, patients could face the closing of our nation's medicine cabinet, with fewer new treatments available. This would be an outcome that would be catastrophic for all of us. Erin Mistry, EVP and Chief Commercial Officer, Cormedix, Inc. Imran Nasrullah, JD., formerly VP & US Head of BD&L at Bayer, and now Founder, SNAP Life Sciences Research and development (R&D) FDA CF Foundation Vertex NIH AMR (antimicrobial resistance) The Pasteur Act HIV Malaria Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy. Genentech Genzyme (Now Sanofi) Medicare IRA (Inflation Reduction Act) COVID-19 Questions or comments?Email us at [email protected] us on social media! Follow us on X, LinkedIn, YouTube and Threads.